EPISODE · May 20, 2026 · 22 MIN
Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib.Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11oApple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Key topics included:Overview of the efficacy and survival data for both combinationsSide effect profiles and management strategiesClinical pearls for oncologists in practiceThe importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapyJoin us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life. Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights!#BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers
What this episode covers
In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib.Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11oApple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Key topics included:Overview of the efficacy and survival data for both combinationsSide effect profiles and management strategiesClinical pearls for oncologists in practiceThe importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapyJoin us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life. Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights!#BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers
NOW PLAYING
Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.